• Je něco špatně v tomto záznamu ?

Ferrocenes as new anticancer drug candidates: Determination of the mechanism of action

H. Skoupilova, M. Bartosik, L. Sommerova, J. Pinkas, T. Vaculovic, V. Kanicky, J. Karban, R. Hrstka,

. 2020 ; 867 (-) : 172825. [pub] 20191123

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023228

Chemotherapy plays an essential role in the management of cancer worldwide. However, it is a non-specific treatment limited by major drawbacks, thus identification and testing of new promising molecular structures representing potential drug candidates are urgently needed. In this work, ferrocene complexes as potential antitumor drugs that display cytotoxicity in low micromolar concentrations against ovarian cancer cells A2780 and SK-OV-3 were investigated to identify their mode of action. Their mechanism of cellular accumulation was studied using differential pulse voltammetry and inductively coupled plasma - mass spectrometry. Their mode of cell death induction was determined by changes in the mitochondrial membrane potential, production of reactive oxygen species and by Annexin V staining. Transferrin receptors were identified as key mediators of intracellular accumulation of ferrocenes and the extent of cellular uptake reflected the anticancer activity of individual compounds. Functional analysis revealed activation of intrinsic apoptosis as a dominant mechanism leading to regulated cell death induced in ovarian cancer cells by ferrocenes. Ferrocenes represent a group of promising sandwich organometallic complexes exerting cytotoxic activity. We suggest their application not only as standalone chemotherapeutics but also as modifying substituents of known drugs to improve their antitumor effects.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023228
003      
CZ-PrNML
005      
20201214125531.0
007      
ta
008      
201125s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejphar.2019.172825 $2 doi
035    __
$a (PubMed)31770527
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Skoupilova, Hana $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653, Brno, Czech Republic.
245    10
$a Ferrocenes as new anticancer drug candidates: Determination of the mechanism of action / $c H. Skoupilova, M. Bartosik, L. Sommerova, J. Pinkas, T. Vaculovic, V. Kanicky, J. Karban, R. Hrstka,
520    9_
$a Chemotherapy plays an essential role in the management of cancer worldwide. However, it is a non-specific treatment limited by major drawbacks, thus identification and testing of new promising molecular structures representing potential drug candidates are urgently needed. In this work, ferrocene complexes as potential antitumor drugs that display cytotoxicity in low micromolar concentrations against ovarian cancer cells A2780 and SK-OV-3 were investigated to identify their mode of action. Their mechanism of cellular accumulation was studied using differential pulse voltammetry and inductively coupled plasma - mass spectrometry. Their mode of cell death induction was determined by changes in the mitochondrial membrane potential, production of reactive oxygen species and by Annexin V staining. Transferrin receptors were identified as key mediators of intracellular accumulation of ferrocenes and the extent of cellular uptake reflected the anticancer activity of individual compounds. Functional analysis revealed activation of intrinsic apoptosis as a dominant mechanism leading to regulated cell death induced in ovarian cancer cells by ferrocenes. Ferrocenes represent a group of promising sandwich organometallic complexes exerting cytotoxic activity. We suggest their application not only as standalone chemotherapeutics but also as modifying substituents of known drugs to improve their antitumor effects.
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a železnaté sloučeniny $x farmakologie $x terapeutické užití $7 D005296
650    _2
$a lidé $7 D006801
650    _2
$a membránový potenciál mitochondrií $x účinky léků $7 D053078
650    _2
$a metaloceny $x farmakologie $x terapeutické užití $7 D000075163
650    _2
$a nádory vaječníků $x farmakoterapie $x patologie $7 D010051
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    _2
$a receptory transferinu $x metabolismus $7 D011990
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bartosik, Martin $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653, Brno, Czech Republic.
700    1_
$a Sommerova, Lucia $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653, Brno, Czech Republic.
700    1_
$a Pinkas, Jiri $u J. Heyrovsky Institute of Physical Chemistry, Academy of Sciences of the Czech Republic, v. v. i., Dolejskova 2155/3, 182 23, Prague 8, Czech Republic.
700    1_
$a Vaculovic, Tomas $u Department of Chemistry, Faculty of Science, Masaryk University, Kamenice 753/5, 62500, Brno, Czech Republic.
700    1_
$a Kanicky, Viktor $u Department of Chemistry, Faculty of Science, Masaryk University, Kamenice 753/5, 62500, Brno, Czech Republic.
700    1_
$a Karban, Jindrich $u Institute of Chemical Process Fundamentals of the CAS, v. v. i., Rozvojova 135, 165 02, Prague 6, Czech Republic.
700    1_
$a Hrstka, Roman $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653, Brno, Czech Republic. Electronic address: hrstka@mou.cz.
773    0_
$w MED00001641 $t European journal of pharmacology $x 1879-0712 $g Roč. 867, č. - (2020), s. 172825
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31770527 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214125530 $b ABA008
999    __
$a ok $b bmc $g 1595547 $s 1113904
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 867 $c - $d 172825 $e 20191123 $i 1879-0712 $m European journal of pharmacology $n Eur J Pharmacol $x MED00001641
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace